FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306353748> ?p ?o ?g. }

• W4306353748 abstract "Effects of low-dose interleukin-2 (IL-2) on the exocrine glandular glands of Sjögren's syndrome are unknown. The aim of this study was to investigate the effects of low-dose IL-2 on salivary gland structure and function in a murine model of Sjögren's syndrome.Non-obese diabetic/Ltj (NOD) mice were used as the animal model of Sjögren's syndrome, and low-dose IL-2 or phosphate buffered saline was administered subcutaneously from 5 weeks of age, while ICR mice were used as controls. Some mice were sacrificed at 9 weeks of age, while the other mice that continued to receive treatment were sacrificed at 23 weeks. We determined the salivary flow rate of mice every 3 weeks during the intervention. After the mice were sacrificed, one submandibular gland was removed for pathological evaluation, while the other submandibular gland was used to measure the levels of 25 cytokines by Luminex technology. Cervical lymph nodes and spleens were examined by flow cytometry for the proportions of CD8+ T cells and Treg cells.The results showed that the salivary flow rate of NOD mice was slower than that of control-group mice, and there were more pathological changes in the submandibular gland. The levels of many cytokines in the submandibular gland were elevated. The proportion of CD8+ T cells in the cervical lymph nodes and spleens was increased; however, the proportion of Treg cells was decreased. After treatment with IL-2, the exocrine function of the salivary glands of mice was improved. IL-2 also promoted the proliferation of Treg cells in the cervical lymph nodes and spleens, but it did not alter the extent of lymphocyte infiltration in the submandibular gland. The levels of cytokines in the submandibular glands, as well as the proportion of CD8+ T cells in the cervical lymph nodes and spleens, were unchanged significantly after IL-2 treatment.Our results demonstrate that treatment with low-dose IL-2 improves the secretory function of the exocrine glands of mice with Sjögren's syndrome, but it does not reverse the structural damage of the exocrine glands." @default.
• W4306353748 created "2022-10-16" @default.
• W4306353748 creator A5002756690 @default.
• W4306353748 creator A5010632162 @default.
• W4306353748 creator A5014432190 @default.
• W4306353748 creator A5055055894 @default.
• W4306353748 creator A5071838180 @default.
• W4306353748 date "2022-10-16" @default.
• W4306353748 modified "2023-10-14" @default.
• W4306353748 title "Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sjögren’s syndrome" @default.
• W4306353748 cites W1567420244 @default.
• W4306353748 cites W1567647760 @default.
• W4306353748 cites W1980074776 @default.
• W4306353748 cites W1984526943 @default.
• W4306353748 cites W2021507425 @default.
• W4306353748 cites W2030314575 @default.
• W4306353748 cites W2042519375 @default.
• W4306353748 cites W2054980104 @default.
• W4306353748 cites W2068113234 @default.
• W4306353748 cites W2078958726 @default.
• W4306353748 cites W2126897233 @default.
• W4306353748 cites W2133915381 @default.
• W4306353748 cites W2138824466 @default.
• W4306353748 cites W2138899248 @default.
• W4306353748 cites W2154224978 @default.
• W4306353748 cites W2465216597 @default.
• W4306353748 cites W2578744507 @default.
• W4306353748 cites W2592935721 @default.
• W4306353748 cites W2594223497 @default.
• W4306353748 cites W2731314347 @default.
• W4306353748 cites W2808296583 @default.
• W4306353748 cites W2808858860 @default.
• W4306353748 cites W2901513648 @default.
• W4306353748 cites W2973404796 @default.
• W4306353748 cites W2979528961 @default.
• W4306353748 cites W2996128776 @default.
• W4306353748 cites W2996404459 @default.
• W4306353748 cites W3127622467 @default.
• W4306353748 cites W3181972838 @default.
• W4306353748 cites W3183662835 @default.
• W4306353748 cites W3196382171 @default.
• W4306353748 cites W4235790631 @default.
• W4306353748 cites W4313324526 @default.
• W4306353748 doi "https://doi.org/10.1186/s12865-022-00524-1" @default.
• W4306353748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36244973" @default.
• W4306353748 hasPublicationYear "2022" @default.
• W4306353748 type Work @default.
• W4306353748 citedByCount "3" @default.
• W4306353748 countsByYear W43063537482023 @default.
• W4306353748 crossrefType "journal-article" @default.
• W4306353748 hasAuthorship W4306353748A5002756690 @default.
• W4306353748 hasAuthorship W4306353748A5010632162 @default.
• W4306353748 hasAuthorship W4306353748A5014432190 @default.
• W4306353748 hasAuthorship W4306353748A5055055894 @default.
• W4306353748 hasAuthorship W4306353748A5071838180 @default.
• W4306353748 hasBestOaLocation W43063537481 @default.
• W4306353748 hasConcept C121332964 @default.
• W4306353748 hasConcept C126322002 @default.
• W4306353748 hasConcept C134018914 @default.
• W4306353748 hasConcept C142724271 @default.
• W4306353748 hasConcept C153400128 @default.
• W4306353748 hasConcept C167672396 @default.
• W4306353748 hasConcept C203014093 @default.
• W4306353748 hasConcept C2778013207 @default.
• W4306353748 hasConcept C2778214642 @default.
• W4306353748 hasConcept C2778690821 @default.
• W4306353748 hasConcept C2778937882 @default.
• W4306353748 hasConcept C2779720271 @default.
• W4306353748 hasConcept C2780266248 @default.
• W4306353748 hasConcept C49039625 @default.
• W4306353748 hasConcept C555293320 @default.
• W4306353748 hasConcept C55851684 @default.
• W4306353748 hasConcept C71924100 @default.
• W4306353748 hasConcept C74172505 @default.
• W4306353748 hasConcept C8891405 @default.
• W4306353748 hasConcept C97355855 @default.
• W4306353748 hasConceptScore W4306353748C121332964 @default.
• W4306353748 hasConceptScore W4306353748C126322002 @default.
• W4306353748 hasConceptScore W4306353748C134018914 @default.
• W4306353748 hasConceptScore W4306353748C142724271 @default.
• W4306353748 hasConceptScore W4306353748C153400128 @default.
• W4306353748 hasConceptScore W4306353748C167672396 @default.
• W4306353748 hasConceptScore W4306353748C203014093 @default.
• W4306353748 hasConceptScore W4306353748C2778013207 @default.
• W4306353748 hasConceptScore W4306353748C2778214642 @default.
• W4306353748 hasConceptScore W4306353748C2778690821 @default.
• W4306353748 hasConceptScore W4306353748C2778937882 @default.
• W4306353748 hasConceptScore W4306353748C2779720271 @default.
• W4306353748 hasConceptScore W4306353748C2780266248 @default.
• W4306353748 hasConceptScore W4306353748C49039625 @default.
• W4306353748 hasConceptScore W4306353748C555293320 @default.
• W4306353748 hasConceptScore W4306353748C55851684 @default.
• W4306353748 hasConceptScore W4306353748C71924100 @default.
• W4306353748 hasConceptScore W4306353748C74172505 @default.
• W4306353748 hasConceptScore W4306353748C8891405 @default.
• W4306353748 hasConceptScore W4306353748C97355855 @default.
• W4306353748 hasFunder F4320321001 @default.
• W4306353748 hasIssue "1" @default.
• W4306353748 hasLocation W43063537481 @default.
• W4306353748 hasLocation W43063537482 @default.

• next